After a series of unfortunate events for BridgeBio Pharma, the biotech may be on a new upward trajectory as it unveiled positive data from 13 patients taking a drug to treat low calcium levels.
BridgeBio shared the phase 2b results this week at the 2022 Annual Meeting of the Endocrine Society held in Atlanta, which showed that the drug, encaleret, restored normal calcium and phosphate metabolism in individuals with a rare genetic condition called autosomal dominant hypocalcemia type 1 (ADH1).
The positive data follow a phase 3 flop in late 2021 for Bridge Bio’s lead asset acoramidis, along with subsequent rounds of layoffs and a tumbling share price.
However, things might be on an upswing for BridgeBio. After cutting down its clinical programs and putting six of its candidates on the block for out-licensing opportunities, the biotech is pinning its hopes on potential value driver encaleret. The oral medicine is being studied in disorders of calcium homeostasis, including ADH1, a condition that is typically inherited and can cause physical, cognitive and emotional symptoms including poor memory, loss of consciousness and seizures.
Click here to read the full article at Fierce Biotech
Disclaimer: BioPharma Global is not responsible for, and expressly disclaims all liability for, damages of any kind arising out of use,
BioPharma Global is a mission-driven corporation dedicated to using our FDA and EMA regulatory expertise and knowledge of various therapeutic areas to help drug developers advance treatments for the disease communities with unmet medical needs. If you are a drug developer seeking regulatory support for Orphan Drug designation, Fast Track designation, Breakthrough Therapy designation, other FDA/EMA expedited programs, type A, B (pre-IND, EOPs), or C meeting assistance, or IND filings, the BioPharma Global team can help. Contact us today to arrange a 30-minute introductory call.